A 21-year-old Muslim, the product of a consanguineous marriage (paternal and maternal grandmothers were sisters) developed progressive papular and erythematosquamous rash over his abdomen on ...

Financing co-led by new investor BRM Group and existing investor Pontifax. Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatm ...

Palmoplantar keratoderma (PPK) is a heterogeneous group of disorders. Epidermolytic PPK is a well delineated autosomal dominant entity, but no recessive form is known. Here we report two sons of ...

Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton Syndrome Until ...

Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected ...

BACKGROUND: Desmosomal gene variants (DGVs) have been associated with a diverse spectrum of phenotypic manifestations within ...

Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

A 24-year-old white male presented with a 2-year history of changes to his nails. He stated that the white discoloration had never completely resolved but improved from time to time with the nails ...

Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and ...

Quoin CEO Dr. Michael Myers said, “The first quarter of 2025 has seen continued momentum across all aspects of our business. We reported compelling data from multiple QRX003 studies in Netherton ...

Patient with palmoplantar keratoderma areata6 It will be quite some time before all rare disease patients can truly say they feel their opinions are taken into account. However the stories of ...